Managing Hematological Cancer Patients During the Covid-19 Pandemic: An ESMO-EHA Interdisciplinary Expert Consensus
Published 27 January 2022 – ESMO OPEN
Authors: C. Buske, M. Dreyling, A. Alvarez-Larrán, J. Apperley, L. Arcaini, C. Besson, L. Bullinger, P. Corradini, M. Giovanni Della Porta, M. Dimopoulos, S.D’Sa, H. T. Eich, R. Foà, P. Ghia, M. G. da Silva, J. Gribben, R. Hajek, C. Harrison, M. Heuser, B. Kiesewetter, J. J. Kiladjian, N. Kröger, P. Moreau, J. R. Passweg, F. Peyvandi, D.Rea, J.-M. Ribera, T. Robak, J. F. San-Miguel, V. Santini, G. Sanz, P. Sonneveld, M. von Lilienfeld-Toal, C. Wendtner, G. Pentheroudakis & F. Passamonti
This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance.